Cleave Biosciences

Cleave Biosciences, founded in 2010, is headquartered in California and is a cancer drug research and development company. Cleave inhibits cancer cell growth and survival by reducing substances necessary for cancer cell proliferation, focusing on developing the next generation of cancer therapies. The company’s leading drug, CB-5083, is an orally administered P97 inhibitor. This innovative P97 inhibitor therapy has the potential to treat various types of cancer, including solid tumors and hematologic malignancies.